Abstracts tagged "Behcet’s syndrome"

Abstract Number: 946 • 2019 ACR/ARP Annual Meeting
Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study
Gulen Hatemi¹, Alfred Mahr ², Mitsuhiro Takeno ³, Doyoung Kim ⁴, Melike Melikoglu ⁵, Sue Cheng ⁶, Shannon McCue ⁷, Maria Paris ⁶, Mindy Chen ⁸ and Yusuf Yazici ⁹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ⁶Celgene Corporation, Summit, ⁷Celgene Corporation, Summit, NJ, ⁸Celgene Corporation, Berkeley Heights, NJ, ⁹New York University School of Medicine, New York
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) that can impair quality of life (QoL). Apremilast (APR),…
Abstract Number: 949 • 2019 ACR/ARP Annual Meeting
Assessment of Femoral Vein Wall Thickness with Doppler Ultrasound Can Be a Diagnostic Tool for Behcet’s Disease
Fatma Alibaz-Oner¹, RABIA ERGELEN ², YASIN YILDIZ ³, Ayten Yazici ⁴, AYDAN MUTIS ⁵, ZEYNEP ERTURK ³, MUSTAFA ALDAG ⁶, Ayşe Cefle ⁷, Bahar Artim-Esen ⁸, GONCA MUMCU ⁹, TULIN ERGUN ¹⁰ and Haner Direskeneli ¹¹, ¹Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ²MARMARA UNIVERSITY, SCHOOL OF MEDICINE, RADIOLOGY, ISTANBUL, Turkey, ³MARMARA UNIVERSITY, SCHOOL OF MEDICINE, RHEUMATOLOGY, ISTANBUL, Turkey, ⁴Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ⁵MARMARA UNIVERSITY, SCHOOL OF MEDICINE, RHEUMATOLOGY, ISTANBUL, Tuvalu, ⁶BAHCESEHIR UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF CARDIOVASCULAR SURGERY, ISTANBUL, Turkey, ⁷Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁸Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁹Marmara, University, Department of Health Management, Marmara University School of Health Sciences, Istanbul, Turkey, ISTANBUL, Turkey, ¹⁰MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DERMATOLOGY, Istanbul, Istanbul, Turkey, ¹¹Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Behcet's disease(BD) is a uniqe systemic vasculitis mainly involving venous vessels in contrast to other systemic vasculitides. Diagnosing BD is a challenge, especially in…
Abstract Number: 1690 • 2019 ACR/ARP Annual Meeting
The Long-term Outcome of Patients with Arthritis of Behçet’s Disease
Hirotoshi Kikuchi¹, Takafumi Tomizuka ¹, Kurumi Asako ¹, Hajime Kono ¹ and Shunsei Hirohata ², ¹Teikyo University School of Medicine, Tokyo, Japan, ²Nobuharra Hospital & Institute of Biomechanics, Tokyo, Japan
Background/Purpose: Behçet’s disease (BD) is characterized by recurrent aphthous stomatitis, eye lesions, skin lesions, and genital ulcer. In addition to these symptoms, Behçet’s disease is…
Abstract Number: 1789 • 2018 ACR/ARHP Annual Meeting
Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey
Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Organ-specific patient-reported outcome (PRO) measures may help management decisions of Behcet’s disease (BD). The aim of this prospective study was to evaluate the factors…
Abstract Number: 1810 • 2018 ACR/ARHP Annual Meeting
Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts
Floor Kerstens¹, Christopher J. Swearingen², Franktien Turkstra¹ and Yusuf Yazici³, ¹Amsterdam Rheumatology & Immunology Centre - Reade, Amsterdam, Netherlands, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome (BS) is formally diagnosed using the International Study Group (ISG) criteria, where recurrent oral ulceration and any two other symptoms (recurrent genital…
Abstract Number: 1790 • 2018 ACR/ARHP Annual Meeting
An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study
Gonca Mumcu¹, Adebowale Adesanya², Aysun Aksoy³, Joice Moraes Faria M Belem⁴, Natalia Borges Cardin⁴, Fatma Alibaz-Oner⁵, Tulin Ergun⁶, Nevsun Inanc⁷, Alexandre W.S. Souza⁸, Wafa Madanat⁹, Farida Fortune¹⁰ and Haner Direskeneli⁷, ¹Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ²Barts and The London, School of Medicine and Dentistry, Institute of Dentistry, Clinical and Diagnostic Oral Sciences, London, UK, London, United Kingdom, ³Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁵Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Istanbul, Turkey, ⁶Department of Dermatology, Faculty of Medicine, Marmara University, Istanbul, Turkey, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁸Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Jordan’s Friends of Behcet’s disease Patients Society, Medical department, Amman, Jordan, Amman, Jordan, ¹⁰Dental Institute, Barts and The London NHS Trust, London, United Kingdom
Background/Purpose: Efficacy of current management approaches for oral ulcer treatment in routine clinical practice is insufficiently explored in Behcet’s disease (BD) patients. The aim of…
Abstract Number: 1811 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
Jing Shi¹, Chan Zhao², Jiaxin Zhou³, JinJing Liu¹, Fei Gao², Xiaofeng Zeng⁴, Meifen Zhang² and Wenjie Zheng¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Uveitis is one of the leading causes of morbidity in Behcet’s patients which may result in irreversible vision loss. Evidence is accumulating that interferon…
Abstract Number: 1791 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Gulen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Do-Young Kim⁴, Melike Melikoglu¹, Sue Cheng⁵, Shannon McCue⁵, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁶, ¹Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Republic of (South), ⁵Celgene Corporation, Summit, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU) that can be disabling and negatively affect quality of life.…
Abstract Number: 1812 • 2018 ACR/ARHP Annual Meeting
Characterization and Prevalence of Morbus Behçet in Switzerland
Sabine Adler¹, Rahel Villiger², Lukas Buetikofer³ and Peter M. Villiger⁴, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Rheumatology, Immunology and Allergology, University Hospital Bern, Switzerland, Bern, Switzerland, ³Clinical Trials Unit, University of Bern, Bern, Switzerland, ⁴Rheumatology and Clin Immunol, Bern, Switzerland
Background/Purpose: To evaluate the clinical presentation of patients with Morbus Behçet (MB) in a cohort from Switzerland and to calculate the prevalence of MB in…
Abstract Number: 1794 • 2018 ACR/ARHP Annual Meeting
Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients
Fatma Alibaz-Oner¹, Rabia Ergelen², Aydan Mutiş³, Zeynep Erturk¹, Ruslan Asadov⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Marmara University School of Medicine, Radiology, ISTANBUL, Turkey, ³Marmara University, School of Medicine, Rheumatology, ISTANBUL, Turkey, ⁴Marmara University School of Medicine, Radiology, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Vascular involvement is seen in up to 40% of the patients with Behcet's Disease (BD), especially in young males and is one of the…
Abstract Number: 1813 • 2018 ACR/ARHP Annual Meeting
Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Muhammed Aydin¹, Bahar Artim-Esen¹, Murat Inanc², Lale Ocal¹ and Ahmet Gül¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Behçet disease (BD) is a multisystem inflammatory disorder characterized by recurrent manifestations in mucocutaneous tissues, eyes, joints, blood vessels, intestines and brain. Since there…
Abstract Number: 1795 • 2018 ACR/ARHP Annual Meeting
New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort
Fatma Alibaz-Oner¹, Belgin Aldag², Emrah Karatay³, Gonca Mumcu⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Radiology, Marmara University, School of Medicine, Istanbul, Turkey, ⁴Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Major organ involvement such as vascular or ocular disease, especially in young males, is one of the main causes of mortality and morbidity in…
Abstract Number: 1814 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series
Yesim Ozguler¹, Gulen Hatemi², Firat Cetinkaya³, Koray Tascilar⁴, Serdal Ugurlu¹, Emire Seyahi¹, Hasan Yazici¹ and Melike Melikoglu¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, ⁴Numune Research and Teaching Hospital, Ankara, Turkey
Background/Purpose: Lower extremity deep vein thrombosis (LEDVT) is a disabling complication of Behcet’s syndrome (BS). Relapses are frequent and cause permanent disability due to post-thrombotic…
Abstract Number: 1796 • 2018 ACR/ARHP Annual Meeting
Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades
Elif Dincses¹, Yesim Ozguler², Didar Ucar³, Yilmaz Ozyazgan⁴, Serdal Ugurlu², Gulen Hatemi², Melike Melikoglu², Sebahattin Yurdakul², Hasan Yazici⁵ and Emire Seyahi², ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁵Istanbul Academic Hospital, Istanbul, Turkey
Background/Purpose: There is some evidence that incident Behcet’s syndrome (BS) might be becoming less severe (1, 2). We compared clinical findings at presentation of BS…
Abstract Number: 1815 • 2018 ACR/ARHP Annual Meeting
Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center
Jiaxin Zhou¹, Jing Shi², Xiuhua Wu², JinJing Liu² and Wenjie Zheng², ¹Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions. Methods: We retrospectively reviewed the clinical data of patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].